Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study

Iris N Poleé; Bregtje C M Hermans; Jan Maarten van der Zwan; Stefan A W Bouwense; Marcus W Dercksen; Ferry A L M Eskens; Bastiaan Havekes; Johannes Hofland; Thomas M A Kerkhofs; Heinz-Josef Klümpen; Loes M Latten-Jansen; Ernst-Jan M Speel; Frederik A Verburg; Annemiek M E Walenkamp; Sandra M E Geurts; Judith de Vos-Geelen

doi:10.1016/j.ejca.2022.06.003

Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study

Iris N Poleé, Bregtje C M Hermans, Jan Maarten van der Zwan, Stefan A W Bouwense, Marcus W Dercksen, Ferry A L M Eskens, Bastiaan Havekes, Johannes Hofland, Thomas M A Kerkhofs, Heinz-Josef Klümpen, Loes M Latten-Jansen, Ernst-Jan M Speel, Frederik A Verburg, Annemiek M E Walenkamp, Sandra M E Geurts, Judith de Vos-Geelen^*

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

Abstract

BACKGROUND: Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) comprise a group of rare malignant tumours with heterogeneous behaviour. This study aimed to assess long-term survival and prognostic factors associated with survival, in order to optimise counselling.

PATIENTS AND METHODS: This population-based study included all GEP-NENs diagnosed between 1989 and 2016 in the Netherlands, selected from the Netherlands Cancer Registry. Overall survival (OS) and relative survival (RS) were calculated. A Cox Proportional Hazard analysis was used to identify prognostic factors (gender, age, tumour stage, location and treatment) for OS. Analyses were stratified by metastatic disease status and tumour grade.

RESULTS: In total, 9697 patients were included. In grade 1, 2 and 3 non-metastatic GEP-NENs (N = 6544), 5-year OS and RS were 81% and 88%, 78% and 83%, and 26% and 30%, respectively. In grade 1 non-metastatic GEP-NENs 10-year OS and RS were 68% and 83%. In grade 1, 2 and 3 metastatic GEP-NENs (N = 3153), 5-year OS and RS rates were 47% and 52%, 38% and 41%, and 5% and 5%, respectively. The highest (relative) survival rates were found in appendicular and rectal NENs, demonstrating 10-year OS and RS of 87% and 93%, and 81% and 95%, respectively.

CONCLUSIONS: These long-term follow-up data demonstrate significant differences in survival for different grades, tumour stage, and primary origin of GEP-NENs, with the most favourable overall and RS rates in patients with non-metastatic grade 1 appendicular and rectal NENs. This study demonstrates unique long-term OS and RS rates using combined stratification by tumour site, grade and stage.

Original language	English
Pages (from-to)	252-263
Number of pages	12
Journal	European Journal of Cancer
Volume	172
Early online date	5 Jul 2022
DOIs	https://doi.org/10.1016/j.ejca.2022.06.003
Publication status	Published - Sept 2022

Keywords

CANCER
Carcinoid
ENETS CONSENSUS GUIDELINES
EPIDEMIOLOGY
EVEROLIMUS
EXPERIENCE
Gastrointestinal
MANAGEMENT
Neuroendocrine tumours
OUTCOMES
PROGNOSTIC-FACTORS
Pancreas
Population-based
Prognosis
RISK-FACTORS
Survival
TUMORS

Access to Document

10.1016/j.ejca.2022.06.003Licence: CC BY

Cite this

Poleé, I. N., Hermans, B. C. M., van der Zwan, J. M., Bouwense, S. A. W., Dercksen, M. W., Eskens, F. A. L. M., Havekes, B., Hofland, J., Kerkhofs, T. M. A., Klümpen, H.-J., Latten-Jansen, L. M., Speel, E.-J. M., Verburg, F. A., Walenkamp, A. M. E., Geurts, S. M. E., & de Vos-Geelen, J. (2022). Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study. European Journal of Cancer, 172, 252-263. https://doi.org/10.1016/j.ejca.2022.06.003

@article{4d1a89bb49a34c41839f9604cd2c2e0b,

title = "Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study",

abstract = "BACKGROUND: Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) comprise a group of rare malignant tumours with heterogeneous behaviour. This study aimed to assess long-term survival and prognostic factors associated with survival, in order to optimise counselling.PATIENTS AND METHODS: This population-based study included all GEP-NENs diagnosed between 1989 and 2016 in the Netherlands, selected from the Netherlands Cancer Registry. Overall survival (OS) and relative survival (RS) were calculated. A Cox Proportional Hazard analysis was used to identify prognostic factors (gender, age, tumour stage, location and treatment) for OS. Analyses were stratified by metastatic disease status and tumour grade.RESULTS: In total, 9697 patients were included. In grade 1, 2 and 3 non-metastatic GEP-NENs (N = 6544), 5-year OS and RS were 81% and 88%, 78% and 83%, and 26% and 30%, respectively. In grade 1 non-metastatic GEP-NENs 10-year OS and RS were 68% and 83%. In grade 1, 2 and 3 metastatic GEP-NENs (N = 3153), 5-year OS and RS rates were 47% and 52%, 38% and 41%, and 5% and 5%, respectively. The highest (relative) survival rates were found in appendicular and rectal NENs, demonstrating 10-year OS and RS of 87% and 93%, and 81% and 95%, respectively.CONCLUSIONS: These long-term follow-up data demonstrate significant differences in survival for different grades, tumour stage, and primary origin of GEP-NENs, with the most favourable overall and RS rates in patients with non-metastatic grade 1 appendicular and rectal NENs. This study demonstrates unique long-term OS and RS rates using combined stratification by tumour site, grade and stage.",

keywords = "CANCER, Carcinoid, ENETS CONSENSUS GUIDELINES, EPIDEMIOLOGY, EVEROLIMUS, EXPERIENCE, Gastrointestinal, MANAGEMENT, Neuroendocrine tumours, OUTCOMES, PROGNOSTIC-FACTORS, Pancreas, Population-based, Prognosis, RISK-FACTORS, Survival, TUMORS",

author = "Pole{\'e}, {Iris N} and Hermans, {Bregtje C M} and {van der Zwan}, {Jan Maarten} and Bouwense, {Stefan A W} and Dercksen, {Marcus W} and Eskens, {Ferry A L M} and Bastiaan Havekes and Johannes Hofland and Kerkhofs, {Thomas M A} and Heinz-Josef Kl{\"u}mpen and Latten-Jansen, {Loes M} and Speel, {Ernst-Jan M} and Verburg, {Frederik A} and Walenkamp, {Annemiek M E} and Geurts, {Sandra M E} and {de Vos-Geelen}, Judith",

year = "2022",

month = sep,

doi = "10.1016/j.ejca.2022.06.003",

language = "English",

volume = "172",

pages = "252--263",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "ELSEVIER SCI LTD",

}

Poleé, IN, Hermans, BCM, van der Zwan, JM, Bouwense, SAW, Dercksen, MW, Eskens, FALM, Havekes, B, Hofland, J, Kerkhofs, TMA, Klümpen, H-J, Latten-Jansen, LM , Speel, E-JM, Verburg, FA, Walenkamp, AME, Geurts, SME & de Vos-Geelen, J 2022, 'Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study', European Journal of Cancer, vol. 172, pp. 252-263. https://doi.org/10.1016/j.ejca.2022.06.003

TY - JOUR

T1 - Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms

T2 - A population-based study

AU - Poleé, Iris N

AU - Hermans, Bregtje C M

AU - van der Zwan, Jan Maarten

AU - Bouwense, Stefan A W

AU - Dercksen, Marcus W

AU - Eskens, Ferry A L M

AU - Havekes, Bastiaan

AU - Hofland, Johannes

AU - Kerkhofs, Thomas M A

AU - Klümpen, Heinz-Josef

AU - Latten-Jansen, Loes M

AU - Speel, Ernst-Jan M

AU - Verburg, Frederik A

AU - Walenkamp, Annemiek M E

AU - Geurts, Sandra M E

AU - de Vos-Geelen, Judith

PY - 2022/9

Y1 - 2022/9

N2 - BACKGROUND: Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) comprise a group of rare malignant tumours with heterogeneous behaviour. This study aimed to assess long-term survival and prognostic factors associated with survival, in order to optimise counselling.PATIENTS AND METHODS: This population-based study included all GEP-NENs diagnosed between 1989 and 2016 in the Netherlands, selected from the Netherlands Cancer Registry. Overall survival (OS) and relative survival (RS) were calculated. A Cox Proportional Hazard analysis was used to identify prognostic factors (gender, age, tumour stage, location and treatment) for OS. Analyses were stratified by metastatic disease status and tumour grade.RESULTS: In total, 9697 patients were included. In grade 1, 2 and 3 non-metastatic GEP-NENs (N = 6544), 5-year OS and RS were 81% and 88%, 78% and 83%, and 26% and 30%, respectively. In grade 1 non-metastatic GEP-NENs 10-year OS and RS were 68% and 83%. In grade 1, 2 and 3 metastatic GEP-NENs (N = 3153), 5-year OS and RS rates were 47% and 52%, 38% and 41%, and 5% and 5%, respectively. The highest (relative) survival rates were found in appendicular and rectal NENs, demonstrating 10-year OS and RS of 87% and 93%, and 81% and 95%, respectively.CONCLUSIONS: These long-term follow-up data demonstrate significant differences in survival for different grades, tumour stage, and primary origin of GEP-NENs, with the most favourable overall and RS rates in patients with non-metastatic grade 1 appendicular and rectal NENs. This study demonstrates unique long-term OS and RS rates using combined stratification by tumour site, grade and stage.

AB - BACKGROUND: Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NENs) comprise a group of rare malignant tumours with heterogeneous behaviour. This study aimed to assess long-term survival and prognostic factors associated with survival, in order to optimise counselling.PATIENTS AND METHODS: This population-based study included all GEP-NENs diagnosed between 1989 and 2016 in the Netherlands, selected from the Netherlands Cancer Registry. Overall survival (OS) and relative survival (RS) were calculated. A Cox Proportional Hazard analysis was used to identify prognostic factors (gender, age, tumour stage, location and treatment) for OS. Analyses were stratified by metastatic disease status and tumour grade.RESULTS: In total, 9697 patients were included. In grade 1, 2 and 3 non-metastatic GEP-NENs (N = 6544), 5-year OS and RS were 81% and 88%, 78% and 83%, and 26% and 30%, respectively. In grade 1 non-metastatic GEP-NENs 10-year OS and RS were 68% and 83%. In grade 1, 2 and 3 metastatic GEP-NENs (N = 3153), 5-year OS and RS rates were 47% and 52%, 38% and 41%, and 5% and 5%, respectively. The highest (relative) survival rates were found in appendicular and rectal NENs, demonstrating 10-year OS and RS of 87% and 93%, and 81% and 95%, respectively.CONCLUSIONS: These long-term follow-up data demonstrate significant differences in survival for different grades, tumour stage, and primary origin of GEP-NENs, with the most favourable overall and RS rates in patients with non-metastatic grade 1 appendicular and rectal NENs. This study demonstrates unique long-term OS and RS rates using combined stratification by tumour site, grade and stage.

KW - CANCER

KW - Carcinoid

KW - ENETS CONSENSUS GUIDELINES

KW - EPIDEMIOLOGY

KW - EVEROLIMUS

KW - EXPERIENCE

KW - Gastrointestinal

KW - MANAGEMENT

KW - Neuroendocrine tumours

KW - OUTCOMES

KW - PROGNOSTIC-FACTORS

KW - Pancreas

KW - Population-based

KW - Prognosis

KW - RISK-FACTORS

KW - Survival

KW - TUMORS

U2 - 10.1016/j.ejca.2022.06.003

DO - 10.1016/j.ejca.2022.06.003

M3 - Article

C2 - 35803176

SN - 0959-8049

VL - 172

SP - 252

EP - 263

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Long-term survival in patients with gastroenteropancreatic neuroendocrine neoplasms: A population-based study

Abstract

Keywords

Access to Document

Fingerprint

Cite this